{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-24-000121","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.022121+00:00","generated_at":"2026-05-31T15:56:56.368645+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance","bullets":["Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).","GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.","Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.","Subcutaneous nivolumab under regulatory review in U.S. and E.U.","CEO Boerner cited progress on commercial execution and pipeline advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-24-000121","json":"https://secwatch.observer/filing/0000014272-24-000121.json","markdown":"https://secwatch.observer/filing/0000014272-24-000121.md","text":"https://secwatch.observer/filing/0000014272-24-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/0000014272-24-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/bmy-20240726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:56:56.368645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}